Search
01/06/2026
Explainable machine learning for continuous transcriptomic modeling of metastatic risk in prostate cancer (MET-score).
Macia, S, Aladid, RL, Tovar, R, Garmendia, L, Lillo, CP, Fossati, M, Romero, ML, Selles, AN, Castellano, D, Gonzalezbilla, E, Maroto-Rey, JP, Piulats, JM, Lista, AGD, Parente, P. Explainable machine learning for continuous transcriptomic modeling of metastatic risk in prostate cancer (MET-score).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.5129. PMID:. IF:41.900(Q1/1D).
01/06/2026
Trabectedin with concomitant radiotherapy in resectable retroperitoneal L-sarcoma: A multicenter, prospective, phase I/II trial-A collaborative study by the Spanish (GEIS), Italian (ISG), and French (FSG) groups.
Alvarez, RMA, Hindi, N, Carrasco-Garcia, I, Sanfilippo, R, Sebio, A, Redondo, A, Alvarez, A, Morosi, C, Romagosa, C, Artigas, V, Casares, CM, Asencio, JM, Guzmán-Gómez, L, González-Lopez, J, Belinchon, B, Sangalli, C, Gutierrez, A, Jurado, JC, Broto, JM, Gronchi, A. Trabectedin with concomitant radiotherapy in resectable retroperitoneal L-sarcoma: A multicenter, prospective, phase I/II trial-A collaborative study by the Spanish (GEIS), Italian (ISG), and French (FSG) groups.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11507. PMID:. IF:41.900(Q1/1D).
01/06/2026
Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno-based regimens
Moura, DS, Mondaza-Hernandez, JL, Shirikova, A, Romero-Gonzalez, P, Carrera, M, Rodriguez, C, Martínez-Trufero, J, Sebio, A, Jurado, JC, Valverde, C, Beveridge, RD, Carrasco-Garcia, I, Gonzalez-Billalabeitia, E, Fernandez-Jara, J, Lopez-Jimenez, C, Hindi, N, Gutierrez, A, Broto, JM. Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno-based regimens. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23526. PMID:. IF:41.900(Q1/1D).
01/06/2026
The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.
Gelderblom, H, Wang, V, Doherty, M, Sebio, A, Stacchiotti, S, Wilky, BA, Blay, JY, Brohl, AS, Morales, CMV, Reichardt, P, Martin-Broto, J, Davis, EJ, De Haan, JJ, O'Neill, B, Babcock, E, Garcia, J, Senne, L, Shepard, D, Chawla, SP, Jones, RL. The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11504. PMID:. IF:41.900(Q1/1D).
01/06/2026
Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non-small cell lung cancer.
Ferrer, L, Nadal, E, Dejean, T, Insa, A, Menu, P, Casal, J, Domine, M, Massuti, B, Majem, M, Martinez-Marti, A, Garcia-Campelo, R, Carpeño, JD, Cobo, M, Vivanco, GL, Morillo, ED, Bernabé, R, Vinolas, N, Barneto, I, Colin, T, Provencio, M. Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non-small cell lung cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8022. PMID:. IF:41.900(Q1/1D).
01/06/2026
Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain
Pacheco-Barcia, V, Obispo, B, Tomas, E, de Torres, CS, Quintanar, T, Paez, D, Leon-Mateos, L, Cancio, H, Cortegoso, A, Anido, U, Quilez, A, Tarazona, N, Jimenez-Labaig, P, Sanchez-Martinez, DA, Goni, AS, Fernandez-Montes, A, Felip, E, Rodriguez, C, Elez, E. Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain. Clinical & Translational Oncology. 2026; 28(6)DOI:10.1007/s12094-025-04171-x. PMID:41436708. IF:2.500(Q3/6D).
01/06/2026
First-in-human phase I study of CEB-01, a biodegradable SN-38-releasing membrane, to prevent local recurrence after resection of retroperitoneal sarcoma: Updated results
González-Lopez, J, Sebio, A, Broto, JM, Hindi, N, Villarejo-Campos, P, Jimenez, M, Díaz-Beveridge, R, Castellanos, JFO, Andajar, RL, Alvarez, RMA, Asencio, JM, Serrano, C, Conde, NR, Castro-Boix, S, Krauel, L, Colom, H, García, JAT, Lopera, E, Huguet, A, Campos, AP. First-in-human phase I study of CEB-01, a biodegradable SN-38-releasing membrane, to prevent local recurrence after resection of retroperitoneal sarcoma: Updated results. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23559. PMID:. IF:41.900(Q1/1D).
01/06/2026
Sex-specific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019-2024).
Garrido, P, Villanueva, N, Bernabé, R, Campelo, RG, Sala, MA, Bote-de Cabo, H, Molla, MAI, Alvarez, R, Cruz, P, Majem, M, Santos, MAM, Cordero, MG, Rodriguez, JMO, Alvarez, RMA, Alvarez-Abril, B, Gutiérrez-Sainz, L, Gutiérrez, V, Munoz-Unceta, N, Felip, E, Isla, D. Sex-specific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019-2024).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8092. PMID:. IF:41.900(Q1/1D).
01/06/2026
Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study.
Broto, JM, Terés, R, Marquina, G, Perez-Fidalgo, JA, Lopez-Jimenez, C, Alonso-Romero, JL, Redondo, A, Gutierrez, A, Casado, A, Sebio, A, Ledesma, P, Merino-Garcia, JA, Mayordomo, E, Moura, DS, Hindi, N. Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11572. PMID:. IF:41.900(Q1/1D).
01/06/2026
Plasma ISG15 as predictor of outcome from antiangiogenic therapy in solitary fibrous tumor: Analysis from the GEIS-69 trial
Mondaza-Hernandez, JL, Moura, DS, Redondo, A, Sebio, A, Beveridge, RD, Martínez-Trufero, J, Romero-Gonzalez, P, Shirikova, A, Rodriguez, C, Carrera, M, Lopez-Jimenez, C, Hindi, N, Broto, JM. Plasma ISG15 as predictor of outcome from antiangiogenic therapy in solitary fibrous tumor: Analysis from the GEIS-69 trial. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23520. PMID:. IF:41.900(Q1/1D).
01/06/2026
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801
Cerezuela-Fuentes, P, Piñero-Madrona, A, Muñoz-Couselo, E, Manzano, JL, Berciano-Guerrero, MA, Majem, M, Espinosa, E, Soria, A, de Miguel, PA, Castaño, AG, Crespo, G, Sanz, LG, de la Rosa, CA, Fernández-Morales, LA, Puértolas, T, Rodríguez, JF, de la Borbolla, MR, Bellido, L, Castro, RL, Pérez, VN, Arroyo, FRG, Guzmán, JCV, Balea, BC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801. Clinical & Translational Oncology. 2026; 28(6)DOI:10.1007/s12094-025-04164-w. PMID:41420791. IF:2.500(Q3/6D).
01/06/2026
Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).
Montañá, JR, Roselló, S, Paez, D, Safont, MJ, Vidal, J, Gravalos, C, Polo, E, Jimenez-Fonseca, P, Calle, SG, Paredes, BG, Beltran, M, Gonzalo-Ruiz, J, Rosales, C, Palmer, HG, Garcia, DL, Nuciforo, P, Vivancos-Prellezo, A, Tabernero, J, Elez, E. Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.TPS3681. PMID:. IF:41.900(Q1/1D).
01/06/2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
Martin-Broto, J, Martinez-Trufero, J, Diaz-Beveridge, R, Gutierrez, A, Carrasco, I, Lopez-Jimenez, C, Sebio, A, González-Billalabeitia, E, Ramos, R, Romagosa, C, Merino, J, Fernandez-Jara, J, Hernandez-Vargas, L, Garmendia, MD, Cruz-Jurado, J, Valverde, C, Mondaza-Hernandez, JL, Carrera, MA, Ledesma, P, Hindi, N, Moura, DS. Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma. CLINICAL CANCER RESEARCH. 2026; 32(11)DOI:10.1158/1078-0432.CCR-26-0032. PMID:41817407. IF:10.200(Q1/1D).
01/06/2026
PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity
Aviles, P, Ribeiro, ML, Guillén, MJ, Martinez-Diez, M, Muñoz-Alonso, MJ, Santamaria-Nuñez, G, Torralba, D, Alamo, P, Gallardo, A, Oliva, MA, Mangues, R, Diaz, JF, Cuevas, C. PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity. MOLECULAR CANCER THERAPEUTICS. 2026; 25(6)DOI:10.1158/1535-7163.MCT-25-0559. PMID:41481906. IF:5.500(Q1/2D).
01/06/2026
Monotherapy vs. combination therapy for Enterococcus faecalis bacteraemia: a target trial emulation
Bartoletti, M, Del Turco, ER, Bussini, L, Paul, M, Sabik, EF, Castagna, A, Ripa, M, Gomes, MZR, Di Bella, S, Malosso, M, Lopez, AB, Franceschini, E, Bandera, A, Barbieri, V, Oliva, A, Munoz, P, Mularoni, A, Seminari, E, Morelli, P, Tascini, C, Papadimitriou-Olivgeris, M, Coppola, N, Cristini, F, Russo, A, Bassetti, M, Travi, G, Contreras, JL, Varisco, B, Viale, P, Cento, V, Gaibani, P, Bavaro, DF, Giannella, M. Monotherapy vs. combination therapy for Enterococcus faecalis bacteraemia: a target trial emulation. CLINICAL MICROBIOLOGY AND INFECTION. 2026; 32(6)DOI:10.1016/j.cmi.2026.03.018. PMID:41850617. IF:8.500(Q1/1D).
01/06/2026
Quality indicators for clinical infectious diseases consultations?results from a hybrid Delphi-nominal group approach and scenario study
Hornuss, D, Mathé, P, Giesen, R, Escolà-Vergé, L, Isler, B, Bartoletti, M, Lamy, B, Wagner, D, Kern, WV, Rieg, S. Quality indicators for clinical infectious diseases consultations?results from a hybrid Delphi-nominal group approach and scenario study. CLINICAL MICROBIOLOGY AND INFECTION. 2026; 32(6)DOI:10.1016/j.cmi.2026.03.006. PMID:41831716. IF:8.500(Q1/1D).
01/06/2026
Long-term Symptom, Psychological, and Functional Outcomes in Patients With Obstructive Sleep Apnea and Excessive Daytime Sleepiness Treated With Cpap: 24-month Results From the Hypnosa Cohort
Lázaro, AR, Mediano, O, Cano-Pumarega, I, Ruiz-Martínez, C, Cristeto, M, Agudo, MA, Lázaro, J, Bozalongo, LP, Vicente, P, Egea, C, Pía, C, Mora, JU, Sánchez, LP, Romero, S, Barrio, PR, Anon, MM, Barbe, F, Dolores, M, Peláez, CM, Podzamczer, I, Fortuna, AM, González, M, de Teran, TD, Dalmases, M, García, J, Alonso-Fernández, A, Bravo, MD, Cabriada-Nuño, V, Gajate, AU, Sanmartí, NG, Farrés, MM, Aguirre, MC, Salord, N, Fontanilles, E, Faus, CC, Pinedo, AR, Navas, IH, Gutiérrez, ML, Arcos, BA, Chinarro, BJ, Avalos, E, Carpi, MM, Perez, RC, Boukichou, N, De La Torre, MS. Long-term Symptom, Psychological, and Functional Outcomes in Patients With Obstructive Sleep Apnea and Excessive Daytime Sleepiness Treated With Cpap: 24-month Results From the Hypnosa Cohort. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2026; 212DOI:10.1093/ajrccm/aamag286.318. PMID:. IF:19.400(Q1/1D).
01/06/2026
Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease
Escolà-Gil, JC, Rotllan, N, Llorente-Cortes, V. Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease. SEMINARS IN CANCER BIOLOGY. 2026; 123DOI:10.1016/j.semcancer.2026.06.001. PMID:42248269. IF:15.700(Q1/1D).
01/06/2026
p19ARF deficiency disrupts lung and lipid homeostasis resembling the human alveolar proteinosis
Jiménez-Garcia, L, Pérez-Montero, A, Herranz, S, Luque, A, Tarín, C, Castillo, D, Lopez-Vilaro, L, Mariñas-Pardo, L, McCarthy, C, Acebo, P, Hortelano, S. p19ARF deficiency disrupts lung and lipid homeostasis resembling the human alveolar proteinosis. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY. 2026; 74(6)DOI:10.1093/ajrcmb/aanag003. PMID:41738246. IF:5.300(Q1/2D).
01/06/2026
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration
Honey, MIJ, Hok-A-Hin, YS, Thijssen, EH, Cousins, KAQ, van der Weijden, B, In't Veld, L, Stoops, E, de Boer, SCM, Duits, FH, de Houwer, JFH, Morrema, THJ, Alcolea, D, Illán-Gala, I, Fortea, J, Lleó, A, Boxer, AL, Irwin, DJ, Lee, EB, Shaw, L, McMillan, CT, Wolk, DA, Hoozemans, JJM, van der Flier, WM, van der Ende, E, Seelaar, H, Verberk, IMW, Gan, L, Pijnenburg, Y, Teunissen, CE. An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration. NATURE MEDICINE. 2026; 32(6)DOI:10.1038/s41591-026-04341-6. PMID:41986736. IF:50.000(Q1/1D).
01/06/2026
Cerebrospinal fluid and plasma leptin dynamics following bariatric surgery in women
Pané, A, Videla, L, Viaplana, J, Ibarzabal, A, Molero, J, Moize, V, Lopez-Ruiz, S, de Hollanda, A, Ortega, E, Barroeta, I, Alcolea, D, Camacho, V, Vidal, J, Chiva-Blanch, G, Fortea, J, Jiménez, A. Cerebrospinal fluid and plasma leptin dynamics following bariatric surgery in women. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2026; 111(6)DOI:10.1210/clinem/dgaf702. PMID:41507035. IF:5.100(Q1/2D).
01/06/2026
How epigenetics impacts stroke risk and outcomes through DNA methylation: A systematic review
Gallego-Fabrega, C, Cullell, N, Fernández-Cadenas, I. How epigenetics impacts stroke risk and outcomes through DNA methylation: A systematic review. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2026; 46(6)DOI:10.1177/0271678X251322032. PMID:40012472. IF:4.500(Q1/2D).
01/06/2026
A Clinician View of the EMA Explanation of the Approval of Amyloid-Targeting Therapies
Jessen, F, Fortea, J. A Clinician View of the EMA Explanation of the Approval of Amyloid-Targeting Therapies. Lancet Regional Health-Europe. 2026; 65DOI:10.1016/j.lanepe.2026.101708. PMID:42180984. IF:13.000(Q1/1D).
01/06/2026
Integrating Planetary Health in Health Guidelines (GRADE Guidance 46)
Piggott, T, Saadat, P, Herrmann, A, Stein, AT, Darzi, AJ, Haines, A, Bognanni, A, Sousa-Pinto, B, Michels, C, Akl, EA, Poluzzi, E, Senerth, E, Madrid, E, Barbic, F, de'Donato, F, Nonino, F, Vist, GE, Neumann, I, Bracchiglione, J, Bousquet, J, Meerpohl, JJ, Antó, JM, Scahill, KA, Qiu, K, Miersch, K, Saif-Ur-Rahman, K, Thinagaran, LV, Benton, L, Schwingshackl, L, Siedler, MR, Bala, MM, Metzendorf, MI, Aloosh, M, Cinquini, M, Cumpston, M, Skoetz, N, Oloyede, O, Alonso-Coello, P, Dahm, P, Wang, Q, Vieira, RJ, Morgan, RL, Murthy, S, Hofstede, S, Laot-Cabon, S, Thomander, T, Siebert, U, Leontiadis, GI, Schünemann, H. Integrating Planetary Health in Health Guidelines (GRADE Guidance 46). ANNALS OF INTERNAL MEDICINE. 2026; 179(6)DOI:10.7326/ANNALS-25-04761. PMID:42114098. IF:15.200(Q1/1D).
01/06/2026
From reserve to the full spectrum of flow quantification in risk prediction
Flotats, A. From reserve to the full spectrum of flow quantification in risk prediction. European Heart Journal-Cardiovascular Imaging. 2026; 27(6)DOI:10.1093/ehjci/jeag063. PMID:41758618. IF:6.600(Q1/1D).
01/06/2026
Randomized controlled trials in Europe: a call to action to protect national healthcare systems from the upcoming tsunami of kidney failure
Ortiz, A, Arici, M, Goumenos, DS, Adamczak, M, Eller, K, Ferreira, AC, Grandaliano, G, Jager, KJ, Lees, JS, Liakopoulos, V, Minutolo, R, Sezer, S, Azzolini, L, Fontana, M, Torres, F, Torra, R. Randomized controlled trials in Europe: a call to action to protect national healthcare systems from the upcoming tsunami of kidney failure. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2026; 41(6)DOI:10.1093/ndt/gfag007. PMID:41578941. IF:5.600(Q1/1D).
01/06/2026
Orthostatic blood pressure reduction is associated with renal damage in functionally preserved elderly hypertensive patients
Ramos-Galí, A, de la Sierra, A, Oliveras, A, Armario, P, Ayasreh, N, Arias, P, Vázquez, S, Camps, C, Castellanos, P, Calero, F, Fernández-Llama, P. Orthostatic blood pressure reduction is associated with renal damage in functionally preserved elderly hypertensive patients. NEFROLOGIA. 2026; 46(6)DOI:10.1016/j.nefro.2026.501521. PMID:42225512. IF:2.600(Q2/4D).
01/06/2026
Renal replacement therapies and adherence to EXTRIP consensus criteria in lithium poisoning: the multicenter SILITOX study
Pineda-Torcuato, A, Caballero-Bermejo, AF, Supervia, A, Salgado, E, O'Laoi, R, Sánchez, C, Córdoba, F, Farré, NR, Sanz-López, N, Ontiveros, HH, Sánchez, BAG, Gallardo, PR, Lobo-Antuña, V, Climent, B, Mora, S, Cózar-Llistó, A, Ortiz, MV, Urroz, M, Samper, VM, Román, PN, Suárez, XC, Moro, FJC, Kennedy, C, Jiménez, MDG, Gispert, MAA, Minguez, M, Sanmillán, IL, Cioccari, L, Pérez, BM, Garcia, SV, Gonzalo, JL, Burillo, G, Gutiérrez, E, Nogué-Xarau, S, Puiguriguer-Ferrando, J, Ruiz-Antorán, B. Renal replacement therapies and adherence to EXTRIP consensus criteria in lithium poisoning: the multicenter SILITOX study. EMERGENCIAS. 2026; 38(3)DOI:10.55633/s3me/040.2026. PMID:42345987. IF:6.300(Q1/1D).
01/06/2026
Analysis of comorbidity in an emergency department using diagnostic coding: The Elixhauser Index
Calvet-Pujol, A, Ris-Romeu, J, Albacar-Ingla, M, Vicente-Diez, F, Navarro-Arranz, P, Puig-Campmany, M. Analysis of comorbidity in an emergency department using diagnostic coding: The Elixhauser Index. EMERGENCIAS. 2026; 38(3)DOI:10.55633/s3me/018.2026. PMID:42345985. IF:6.300(Q1/1D).
01/06/2026
Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping study
Vyvey, E, Soenen, R, Oon, HH, Mburu, S, Awici-Rasmussen, M, Affandi, AM, Gulliver, W, Choon, SE, Torres, T, Fitzgerald, A, Gonzalez-Cantero, A, López-Ferrer, A, Lee, CH, Valenzuela, F, Maul, J, Puig, L, Okuse, M, EL-Komy, M, Foley, P, Vender, R, Boehncke, W, Pohunek, J, Wang, YH, Londoño-García, A, Todd, G, Velasquez-Lopera, M, Lebwohl, M, Lau, E, Schmitt-Egenolf, M, Hilhorst, N, Connell, S, Deprez, E, Van Geel, N, Griffiths, C, van de Kerkhof, P, Lambert, J. Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2026; 40(6)DOI:10.1111/jdv.70313. PMID:41641893. IF:8.000(Q1/1D).
01/06/2026
Diagnostic Modalities and Nodal Staging in High-Risk Cutaneous Squamous Cell Carcinoma
Ferrándiz-Pulido, C, Gómez-Tomás, A, Siurana, S, Tortajada, C, Salido-Vallejo, R, Aguayo-Ortiz, RS, Amorós, IR, Turrión-Merino, L, Alvarez, BB, González, IP, Martí-Marti, I, Medrano-Martorell, S, Podlipnik, S, Mollet, J, Masferrer, E, Lopez-Castillo, D, Yébenes, M, Corbacho-Monné, M, Leal, L, Solano-López, A, Ruiz-Salas, V, Granell-Moreno, E, Alfonso, S, Mendoza, MD, Martínez-Domenech, A, Juárez-Dobjanschi, C, González, ES, Díaz, P, Toll, A. Diagnostic Modalities and Nodal Staging in High-Risk Cutaneous Squamous Cell Carcinoma. JAMA Dermatology. 2026; 162(6)DOI:10.1001/jamadermatol.2026.0803. PMID:42018290. IF:11.000(Q1/1D).
01/06/2026
Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
de la Fuente, EG, Herrera, E, Esquerdo, IME, Sarró, DV, Figueras-Nart, I, Salvador, JFS, Gilaberte, Y, Alarcón, SS, Serra-Baldrich, E, Campos, MM, Moro, RM, Díaz-Cerezo, S, Moyano, S, Talavera-Rodríguez, I, Núñez, M. Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review. Dermatology and Therapy. 2026; 16(6)DOI:10.1007/s13555-026-01737-7. PMID:42014530. IF:4.200(Q1/1D).
01/06/2026
Multidisciplinary Management in Psoriasis: A Structured Approach for Early Comorbidity Detection and Referral
López-Ferrer, A, González-Cantero, A, Gutiérrez-Casbas, A, Martorell, A, Olveira, A, Madrid-Alvarez, MB, Nicolau, J, Carrascosa, JM, Baniandrés, O, Rivera, R, Ruiz-Villaverde, R, Queiro, R, de la Cueva, P. Multidisciplinary Management in Psoriasis: A Structured Approach for Early Comorbidity Detection and Referral. Dermatology and Therapy. 2026; 16(6)DOI:10.1007/s13555-026-01759-1. PMID:41999535. IF:4.200(Q1/1D).
01/06/2026
Chronic Venous Disease in Patients With Hidradenitis Suppurativa and Lymphedema: An Overlooked Problem
Garbayo-Salmons, P, Molina-Leyva, A, Aguayo-Ortiz, RS, Vilarrasa, E. Chronic Venous Disease in Patients With Hidradenitis Suppurativa and Lymphedema: An Overlooked Problem. Jeadv Clinical Practice. 2026; 5(2)DOI:10.1002/jvc2.70300. PMID:. IF:(Q/D).
01/06/2026
Durvalumab (D) in combination with BCG induction and maintenance (I plus M) therapy for BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.
De Santis, M, Shore, ND, Nishiyama, H, Krawczynski, M, Seyitkuliev, A, Guerrero-Ramos, F, Zukov, R, Kawahara, T, Goeman, L, Powles, T, Gust, KM, Feyerabend, S, Patel, M, Kulkarni, GS, Lebret, T, Westgeest, HM, Quartilho, A, Dabrowska, A, Marsh, A, Palou, J. Durvalumab (D) in combination with BCG induction and maintenance (I plus M) therapy for BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.4624. PMID:. IF:41.900(Q1/1D).
01/06/2026
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study
Zaurito, P, Scilipoti, P, Longoni, M, de Angelis, M, Slusarczyk, A, Viti, A, Santangelo, A, Tremolada, G, Soria, F, Pradere, B, Krajewski, W, D'Andrea, D, Mari, A, Del Giudice, F, Pichler, R, Subiela, JD, Marcq, G, Gallioli, A, Afferi, L, Mastroianni, R, Simone, G, Albisinni, S, Mertens, LS, Laukhtina, E, Oberneder, K, Elena, JLR, Arandar, J, Puentedura, AL, Velascos, JC, Contieri, R, Hurle, R, Mori, K, Radziszewski, P, Shariat, SF, Gontero, P, Rouprêt, M, Montorsi, F, Salonia, A, Briganti, A, Moschini, M. Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2026; 44(6)DOI:10.1016/j.urolonc.2026.111089. PMID:41934021. IF:2.300(Q2/5D).
01/06/2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin
Scilipoti, P, Zaurito, P, Longoni, M, Occhi, A, de Angelis, M, Disabato, N, Tremolada, G, Barracco, S, Slusarczyk, A, Soria, F, Krajewski, W, D'Andrea, D, Mari, A, Del Giudice, F, Pichler, R, Subiela, JD, Marcq, G, Gallioli, A, Afferi, L, Mastroianni, R, Simone, G, Albisinni, S, Mertens, LS, Laukhtina, E, Oberneder, K, Elena, JLR, Aranda, J, Puentedura, AL, Velasco, JC, Contieri, R, Hurle, R, Mori, K, Radziszewski, P, Shariat, SF, Gontero, P, Rouprêt, M, Pradere, B, Montorsi, F, Briganti, A, Moschini, M. The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2026; 44(6)DOI:10.1016/j.urolonc.2026.111085. PMID:41967989. IF:2.300(Q2/5D).
01/06/2026
A new machine learning model to predict novel trifecta achievement and validation of its prognostic significance in a large single centre series of minimally invasive partial nephrectomy
Farré, A, Uleri, A, Gallioli, A, Baboudjian, M, Sanz, I, Casadevall, M, Hernández, P, Territo, A, Gavrilov, P, Faba, OR, Huguet, J, Gaya, JM, Palou, J, Breda, A. A new machine learning model to predict novel trifecta achievement and validation of its prognostic significance in a large single centre series of minimally invasive partial nephrectomy. Actas Urologicas Espanolas. 2026; 50(5)DOI:10.1016/j.acuro.2025.501900. PMID:41490536. IF:1.200(Q3/7D).
01/06/2026
Respiratory muscle activity and weaning from mechanical ventilation after spinal trauma: the ACCESSIT study
Schreiber, AF, Vieira, F, Madotto, F, Sousa, MLA, Rodrigues, A, Ko, MT, Phoophiboon, V, McFarlan, AW, Brault, C, Subirà, C, Singh, JM, Reid, WD, Rigamonti, A, Baker, A, Witiw, CD, Brochard, LJ. Respiratory muscle activity and weaning from mechanical ventilation after spinal trauma: the ACCESSIT study. Annals of the American Thoracic Society. 2026; 23(6)DOI:10.1093/annalsats/aaoag046. PMID:41723830. IF:5.400(Q1/2D).
01/06/2026
Bone Marrow Aspirate Concentrate Improves the Early Osseous Integration of Fresh Osteochondral Allografts in the Knee: A Randomized Controlled Trial
Gelber, PE, Ramírez-Bermejo, E, Caviasso, G, Juncosa-Chacón, J, Fariñas, O. Bone Marrow Aspirate Concentrate Improves the Early Osseous Integration of Fresh Osteochondral Allografts in the Knee: A Randomized Controlled Trial. AMERICAN JOURNAL OF SPORTS MEDICINE. 2026; 54(7)DOI:10.1177/03635465261437779. PMID:41992571. IF:4.500(Q1/1D).